No escape for GBM

Glionova AB's preclinical candidate for glioblastoma multiforme, GLN-1001, exploits an altered tumor biology that has yet to demonstrate an evasion mechanism. The company expects the mechanism could provide an advantage over more advanced candidates that have demonstrated a survival benefit but could result in resistance because they target specific genetic mutations.

Glionova launched Nov. 12 with a SEK42 million (.5 million) series A round co-led by HealthCap and Novo Seeds...